PULMOZYME Side Effects

6946308-7 | Pneumonia Streptococcal
on Aug 19, 2010 Male patient from UNITED STATES , weighting 111.3 lb, was treated with Pulmozyme (View Usage). Patient experienced the following unwanted or unexpected effects: pneumonia streptococcal. Pulmozyme dosage: Unk. During the same period patient was treated with FLONASE (Unk) (View Flonase Review and Flonase Label ), ALBUTEROL (View Albuterol Review and Albuterol Label ), SALINE (View Saline Review and Saline Label ), ADVAIR DISKUS 100/50 (View Advair Diskus 100/50 Review and Advair Diskus 100/50 Label ), PROVENTIL (View Proventil Review and Proventil Label ), DAILY VITAMIN (View Daily Vitamin Review and Daily Vitamin Label ), VITAMIN D (View Vitamin D Review and Vitamin D Label ), OMEPRAZOLE (View Omeprazole Review and Omeprazole Label ). Patient was hospitalized.

6888124-0 | Chest Discomfort, Dyspnoea, Product Quality Issue, Pulmonary Function Test Decreased
Patient was taking Pulmozyme (View Usage). Patient had the following side effects: chest discomfort, dyspnoea, product quality issue, pulmonary function test decreased on Jul 22, 2010 from UNITED STATES Additional patient health information: Male patient , weighting 185.0 lb, was diagnosed with cystic fibrosis and. Pulmozyme dosage: 2.5 Ml, Bid. During the same period patient was treated with CREON (View Creon Review and Creon Label ), BROVANA (View Brovana Review and Brovana Label ), TOBRAMYCIN (View Tobramycin Review and Tobramycin Label ). Patient was hospitalized.

6872281-6 | Chest Discomfort, Dyspnoea, Pulmonary Function Test Decreased
Adverse event was reported on Jul 16, 2010 by a Male patient taking Pulmozyme (View Usage) (Dosage: 2.5 Ml, Bid) was diagnosed with cystic fibrosis and. Location: UNITED STATES , weighting 185.0 lb, After Pulmozyme was administered, patient had the following side effects: chest discomfort, dyspnoea, pulmonary function test decreased. During the same period patient was treated with CREON (View Creon Review and Creon Label ), BROVANA (View Brovana Review and Brovana Label ), TOBRAMYCIN (View Tobramycin Review and Tobramycin Label ). Patient was hospitalized.

6754237-7 | Cystic Fibrosis
on May 26, 2010 Male patient from UNITED STATES , child 12 years of age, was diagnosed with cystic fibrosis, endotracheal intubation and was treated with Pulmozyme (View Usage). Patient experienced the following unwanted or unexpected effects: cystic fibrosis. Pulmozyme dosage: . Patient was hospitalized.


6654706-4 | Grand Mal Convulsion, Urinary Incontinence
on Mar 17, 2010 Female patient from UNITED KINGDOM , 30 years of age, weighting 144.6 lb, was diagnosed with cystic fibrosis and was treated with Pulmozyme (View Usage). Patient had the following side effects: grand mal convulsion, urinary incontinence (What is urinary incontinence?). Pulmozyme dosage: 2.5 Mg, Unk. During the same period patient was treated with FLOXACILLIN SODIUM (1 G, Unk) (View Floxacillin Sodium Review and Floxacillin Sodium Label ), MONTELUKAST SODIUM (10 Mg, Unk) (View Montelukast Sodium Review and Montelukast Sodium Label ), OMEPRAZOLE (20 Mg, Unk) (View Omeprazole Review and Omeprazole Label ).

6527976-0 | Body Temperature Increased, Chills, Dehydration, Dry Skin, Heart Rate Increased, Hypophagia, Lip Ulceration, Mouth Ulceration, Nausea
Patient was taking Pulmozyme (View Usage). After Pulmozyme was administered, patient had the following side effects: body temperature increased, chills, dehydration, dry skin, heart rate increased, hypophagia, lip ulceration, mouth ulceration, nausea (What is nausea?) on Jan 05, 2010 from UNITED STATES Additional patient health information: Female patient , weighting 117.1 lb, . Pulmozyme dosage: . Patient was hospitalized.

6403686-5 | Haemoptysis
Adverse event was reported on Oct 05, 2009 by a Female patient taking Pulmozyme (View Usage) (Dosage: 2.5 Mg, Unk) was diagnosed with cystic fibrosis and. Location: UNITED KINGDOM , 30 years of age, Patient experienced the following unwanted or unexpected effects: haemoptysis. During the same period patient was treated with ACETYLCYSTEINE (View Acetylcysteine Review and Acetylcysteine Label ), ALENDRONIC ACID (Unk) (View Alendronic Acid Review and Alendronic Acid Label ), AZITHROMYCIN (View Azithromycin Review and Azithromycin Label ), CALCIUM (Unk) (View Calcium Review and Calcium Label ), VITAMINS + MINERALS (View Vitamins + Minerals Review and Vitamins + Minerals Label ), CEFTAZIDIME (Unk) (View Ceftazidime Review and Ceftazidime Label ), CHLORAMPHENICOL (Unk) (View Chloramphenicol Review and Chloramphenicol Label ), COLISTIMETHATE SODIUM (Unk) (View Colistimethate Sodium Review and Colistimethate Sodium Label ). Patient was hospitalized.

6072862-6 | Abdominal Pain, Nausea, Urticaria
on Jan 13, 2009 Male patient from UNITED KINGDOM , child 7 years of age, was diagnosed with immotile cilia syndrome and was treated with Pulmozyme (View Usage). Patient had the following side effects: abdominal pain (What is abdominal pain?), nausea (What is nausea?), urticaria. Pulmozyme dosage: Unk. Patient was hospitalized.

5964363-8 | Eosinophil Count Decreased, Malaise, Rash
on Nov 10, 2008 Female patient from SWITZERLAND , weighting 74.96 lb, was diagnosed with bronchopulmonary aspergillosis allergic and was treated with Pulmozyme (View Usage). After Pulmozyme was administered, patient had the following side effects: eosinophil count decreased, malaise, rash (What is rash?). Pulmozyme dosage: . During the same period patient was treated with XOLAIR (300 Mg, Unk) (View Xolair Review and Xolair Label ), MEDROL (10 Mg, 1/week) (View Medrol Review and Medrol Label ), SODIUM CHLORIDE (6 %, Unk) (View Sodium Chloride Review and Sodium Chloride Label ), AMUKIN (View Amukin Review and Amukin Label ), INTERFERON GAMMA 1B (View Interferon Gamma-1b Review and Interferon Gamma-1b Label ), LANTUS (View Lantus Review and Lantus Label ), OMEPRAZOLE (View Omeprazole Review and Omeprazole Label ), ETHAMBUTOL HYDROCHLORIDE (View Ethambutol Hydrochloride Review and Ethambutol Hydrochloride Label ).

5964362-6 | Eosinophil Count Decreased, Malaise, Rash
Patient was taking Pulmozyme (View Usage). Patient experienced the following unwanted or unexpected effects: eosinophil count decreased, malaise, rash (What is rash?) on Nov 10, 2008 from SWITZERLAND Additional patient health information: Female patient , weighting 74.96 lb, was diagnosed with bronchopulmonary aspergillosis allergic and. Pulmozyme dosage: . During the same period patient was treated with XOLAIR (300 Mg, Unk) (View Xolair Review and Xolair Label ), MEDROL (10 Mg, 1/week) (View Medrol Review and Medrol Label ), SODIUM CHLORIDE (6 %, Unk) (View Sodium Chloride Review and Sodium Chloride Label ), AMUKIN (View Amukin Review and Amukin Label ), INTERFERON GAMMA 1B (View Interferon Gamma-1b Review and Interferon Gamma-1b Label ), LANTUS (View Lantus Review and Lantus Label ), OMEPRAZOLE (View Omeprazole Review and Omeprazole Label ), ETHAMBUTOL HYDROCHLORIDE (View Ethambutol Hydrochloride Review and Ethambutol Hydrochloride Label ).

5962491-4 | Eclampsia, Pregnancy, Premature Labour
Adverse event was reported on Apr 09, 2008 by a Female patient taking Pulmozyme (View Usage) (Dosage: Unk) was diagnosed with cystic fibrosis and. Location: UNITED KINGDOM , 16 years of age, Patient had the following side effects: eclampsia, pregnancy (What is pregnancy?), premature labour.

5960773-3 | Haemoptysis
on May 29, 2007 Female patient from UNITED KINGDOM , child 10 years of age, was diagnosed with cystic fibrosis and was treated with Pulmozyme (View Usage). After Pulmozyme was administered, patient had the following side effects: haemoptysis. Pulmozyme dosage: Unk.

5957445-8 | Haemoptysis
on May 10, 2007 Female patient from UNITED KINGDOM , 21 years of age, was treated with Pulmozyme (View Usage). Patient experienced the following unwanted or unexpected effects: haemoptysis. Pulmozyme dosage: .

5957420-3 | Cervical Dysplasia
Patient was taking Pulmozyme (View Usage). Patient had the following side effects: cervical dysplasia on Apr 01, 2008 from UNITED KINGDOM Additional patient health information: Female patient , 22 years of age, was diagnosed with cystic fibrosis and. Pulmozyme dosage: Unk. Patient was hospitalized.

5754786-4 | Caesarean Section
Adverse event was reported on May 29, 2008 by a Female patient taking Pulmozyme (View Usage) (Dosage: 2.5 Mg, Qd) was diagnosed with cystic fibrosis and. Location: IRELAND , weighting 110.2 lb, After Pulmozyme was administered, patient had the following side effects: caesarean section. During the same period patient was treated with TAZOCIN (View Tazocin Review and Tazocin Label ), FORTUM (View Fortum Review and Fortum Label ), CREON (View Creon Review and Creon Label ), FOLIC ACID (View Folic Acid Review and Folic Acid Label ), ALBUTEROL (View Albuterol Review and Albuterol Label ), LIQUIGEN (View Liquigen Review and Liquigen Label ), TOBRAMYCIN (View Tobramycin Review and Tobramycin Label ), SERETIDE (View Seretide Review and Seretide Label ).

5464603-8 | Pulmonary Haemorrhage
on Sep 13, 2007 Male patient from UNITED STATES , 14 years of age, was diagnosed with cystic fibrosis and was treated with Pulmozyme (View Usage). Patient experienced the following unwanted or unexpected effects: pulmonary haemorrhage. Pulmozyme dosage: 2.5 Ml, Qod.

5290924-8 | Neoplasm Malignant
on Apr 07, 2007 Male patient from UNITED STATES , 23 years of age, was diagnosed with cystic fibrosis and was treated with Pulmozyme (View Usage). Patient had the following side effects: neoplasm malignant. Pulmozyme dosage: . Patient was hospitalized.

5242113-0 | Disease Progression, Neoplasm Malignant
Patient was taking Pulmozyme (View Usage). After Pulmozyme was administered, patient had the following side effects: disease progression, neoplasm malignant on Feb 03, 2007 from UNITED STATES Additional patient health information: Male patient , 23 years of age, was diagnosed with cystic fibrosis and. Pulmozyme dosage: . Patient was hospitalized.

5107562-X | Bradycardia, Bronchospasm, Cardiac Arrest, Oxygen Saturation Decreased
Adverse event was reported on Sep 13, 2006 by a Male patient taking Pulmozyme (View Usage) (Dosage: 2.5 Mg 2 Times Daily Inhal) was diagnosed with respiratory failure and. Location: UNITED STATES , weighting 9.04 lb, Patient experienced the following unwanted or unexpected effects: bradycardia, bronchospasm, cardiac arrest (What is cardiac arrest?), oxygen saturation decreased.

5062454-X | Bronchospasm, Pyrexia
on Jul 20, 2006 Male patient from UNITED STATES , 52 years of age, was diagnosed with cystic fibrosis and was treated with Pulmozyme (View Usage). Patient had the following side effects: bronchospasm, pyrexia. Pulmozyme dosage: . Patient was hospitalized.

5018266-6 | Gastric Ulcer, Oesophageal Ulcer, Weight Decreased
on May 20, 2006 Female patient from BRAZIL , child 5 years of age, was diagnosed with cystic fibrosis and was treated with Pulmozyme (View Usage). After Pulmozyme was administered, patient had the following side effects: gastric ulcer, oesophageal ulcer, weight decreased. Pulmozyme dosage: 2.5 Mg, Qd; Nasal. During the same period patient was treated with OMEPRAZOLE (View Omeprazole Review and Omeprazole Label ).

4924975-7 | Gastric Ulcer, Oesophageal Ulcer, Weight Decreased
Patient was taking Pulmozyme (View Usage). Patient experienced the following unwanted or unexpected effects: gastric ulcer, oesophageal ulcer, weight decreased on Feb 10, 2006 from BRAZIL Additional patient health information: Female patient , child 5 years of age, was diagnosed with cystic fibrosis and. Pulmozyme dosage: 2.5 Mg; Qd, Nasal. During the same period patient was treated with OMEPRAZOLE (View Omeprazole Review and Omeprazole Label ).

4868635-X | Pyrexia
Adverse event was reported on Dec 12, 2005 by a Male patient taking Pulmozyme (View Usage) (Dosage: ) was diagnosed with cystic fibrosis and. Location: UNITED STATES , 52 years of age, Patient had the following side effects: pyrexia. Patient was hospitalized.